DiaCarta
DiaCarta Gets CE-IVD Mark for SARS CoV-2, Flu A/B Combo Test
The QuantiVirus SARS-CoV-2 Flu A/B Detection Test identifies and distinguishes the three viruses in a single tube using nasopharyngeal swab or saliva samples.
DiaCarta to Explore XNA Clamp Tech for Low-Frequency Mutations Under NIH Collaboration
Working under a two-year cooperative R&D agreement, the firm will explore its platform for cancer and rare disease mutation detection and in situ cancer cell analyses.
DiaCarta Molecular Test for SARS-CoV-2, Variants Obtains CE Mark
The firm is also pursuing FDA Emergency Use Authorization for its SARS-CoV-2 variant detection test, which uses molecular clamping technology.
The firm has launched a validation trial for its in-development QuantiDNA cell-free DNA chemotherapy response assay in late-stage smoking-related cancers.
FDA Grants Emergency Use Authorization for DiaCarta Multiplex Coronavirus Test
The test is designed to detect the SARS-CoV-2 Orf1ab gene in upper respiratory specimens and sputum, according to the California-based company.